Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bioverativ

- PMLiVE

Victoza cuts cardiovascular risk in landmark study

Novo Nordisk’s diabetes therapy outcomes ‘beyond expectations’

Sanofi reception

Sanofi boosted by iGlarLixi trials at ADA

Combination of Lantus and Lyxumia showed greater efficacy in controlling type 2 diabetes

- PMLiVE

A rare opportunity

Sobi’s Neil Dugdale on how the UK’s approach to rare diseases is changing

Deal Watch May 2016

Novartis, Quintiles and Sanofi are among those featured in this month’s round-up of pharma deal activity

- PMLiVE

GSK and J&J move closer to sirukumab filing for arthritis

On course for third quarter application in a bid to catch up with Sanofi’s sarilumab

Biogen Idec building

Biogen multiple sclerosis drug flunks clinical trial

Opicinumab had been proposed as a possible reparative therapy in MS

Shire Basingstoke

Shire completes $32bn Baxalta merger

Creates world leading rare diseases specialist

Biogen Idec building

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Once-monthly, self-administered Zinbryta ‘significantly’ reduces relapse rate

EU flag

Second Remicade biosimilar given green light in Europe

Samsung Bioepis’ Flixabi provides another lower-cost treatment option

National Institute for Health and Care Excellence NICE logo

NICE gives green light to Sanofi’s Jevtana for prostate cancer

Undisclosed discount for NHS encourages U-turn to back the chemotherapy drug

Sanofi reception

FDA panel backs Sanofi’s insulin/GLP-1 agonist combo

iGlarLixi secures endorsement despite concern over its dosing and delivery device

Sanofi Pascale Witz

Sanofi’s diabetes head Pascale Witz to leave the company

She will be replaced by Peter Guenter as part of an executive reshuffle

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links